Radical prostatectomy (RP), a definitive therapy for PC, is recommended for certain patients with high-risk PC (HRPC; prostate-specific antigen (PSA) ≥ 20 ng/mL, Gleason score (GS) ≥ 8, or clinical stage ≥ cT3a) [4,5]. Here, KLK3 is linked to pachyonychia congenita.